Brain-Focused Startup Oyster Gets $60M to Beat the Size Problem for Small Molecule Degraders

Oyster Therapeutics’ lead program penetrates the brain to degrade pathological tau associated with Alzheimer’s disease. Eli Lilly, maker of the amyloid-targeting Alzheimer’s drug Kisunla, participated in the startup’s new financing. The post Brain-Focused Startup Oyster Gets $60M to Beat the Size Problem for Small Molecule Degraders appeared first on MedCity News.

Read More

The Advancing Global Health Annual Program Statement (AGH/APS) Mechanism: Supplementing the America First MOUs 

To shed greater light on U.S. global health efforts under the AFGHS, this analysis examines the Advancing Global Health APS (AGH/APS) award opportunities announced to date by looking at how funding may be directed across countries and selected areas of global health programming, painting a fuller picture of how continued U.S. global health investment may…

Read More